Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Future oncology (London, England)·2026
Same author

Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.

Leukemia & lymphoma·2026
Same author

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.

Future oncology (London, England)·2026
Same author

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

Current medical research and opinion·2026

Related Experiment Video

Updated: Dec 17, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K

Selinexor in relapsed/refractory multiple myeloma.

Joshua Richter1, Deepu Madduri2, Shambavi Richard2

  • 1Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Ringgold Standard Institution - Hematology/Oncology, 1 Gustave L. Levy Pl., New York, NY 10029, USA.

Therapeutic Advances in Hematology
|June 23, 2020
PubMed
Summary

Selinexor, an exportin-1 inhibitor, offers new hope for multiple myeloma (MM) patients with relapsed or refractory disease. Combination therapies including Selinexor show promise for controlling this incurable hematologic malignancy.

Keywords:
SINEmyelomarelapsed/refractoryselinexor

More Related Videos

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.8K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

450

Related Experiment Videos

Last Updated: Dec 17, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.8K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

450

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) is an incurable blood cancer where patients often relapse after treatment.
  • New therapies like immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies have improved outcomes but haven't cured MM.
  • Selinexor is a novel exportin-1 inhibitor showing efficacy in heavily pretreated MM patients.

Purpose of the Study:

  • To evaluate the efficacy of Selinexor-based combination regimens in patients with relapsed and refractory multiple myeloma.
  • To explore Selinexor's potential in triple-class refractory MM, a group with limited therapeutic options.

Main Methods:

  • Clinical trials are investigating Selinexor in combination with other anti-myeloma agents.
  • Evaluating triplet and quadruplet regimens incorporating Selinexor.
  • Assessing patient response and disease control in refractory MM populations.

Main Results:

  • Selinexor-based triplet and quadruplet regimens demonstrate significant activity in triple-class refractory MM patients.
  • These combinations offer potential new treatment options for patients with limited prior therapies.
  • Selinexor shows promise in managing multiply relapsed and refractory MM.

Conclusions:

  • Selinexor-based combinations represent a promising therapeutic strategy for relapsed/refractory multiple myeloma.
  • Careful selection of drug combinations, dosing, and supportive care are crucial for successful treatment.
  • Patients with previously untreatable MM now have potential regimens to control their disease with Selinexor combinations.